[go: up one dir, main page]

WO1998039464A3 - Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same - Google Patents

Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same Download PDF

Info

Publication number
WO1998039464A3
WO1998039464A3 PCT/US1998/004080 US9804080W WO9839464A3 WO 1998039464 A3 WO1998039464 A3 WO 1998039464A3 US 9804080 W US9804080 W US 9804080W WO 9839464 A3 WO9839464 A3 WO 9839464A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
adenoviral
adenovirus vectors
methods
heterologous
Prior art date
Application number
PCT/US1998/004080
Other languages
French (fr)
Other versions
WO1998039464A8 (en
WO1998039464A9 (en
WO1998039464A2 (en
Inventor
Daniel R Henderson
De-Chao Yu
Henry G Lamparski
Original Assignee
Calydon Inc
Daniel R Henderson
Yu De Chao
Henry G Lamparski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/033,556 external-priority patent/US6432700B1/en
Application filed by Calydon Inc, Daniel R Henderson, Yu De Chao, Henry G Lamparski filed Critical Calydon Inc
Priority to EP98907702A priority Critical patent/EP1007715A2/en
Priority to AU63450/98A priority patent/AU744725B2/en
Priority to JP53867498A priority patent/JP2002514074A/en
Priority to CA002283231A priority patent/CA2283231C/en
Publication of WO1998039464A2 publication Critical patent/WO1998039464A2/en
Publication of WO1998039464A3 publication Critical patent/WO1998039464A3/en
Publication of WO1998039464A9 publication Critical patent/WO1998039464A9/en
Publication of WO1998039464A8 publication Critical patent/WO1998039464A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Replication-competent adenovirus vectors specific for target cells and methods of use of such viruses are provided. These adenoviruses comprise a first adenoviral gene under control of a cell specific heterologous (i.e., non-adenoviral) transcriptional regulatory element (TRE) and at least a second gene under control of a second heterologous TRE, where the heterologous TREs are different from each other in polynucleotide sequence but functional in the same cell. The adenoviral gene can be, for example, a gene required for adenoviral replication. The second gene can be, for example, a second adenoviral gene or a transgene, such as a gene which can contribute to cytotoxicity in the target cell. Adenoviral replication can be restricted to target cells in which the heterologous TREs are functional and thus, the adenovirus vectors can provide selective cytotoxicity to the target cells, particularly neoplastic cells.
PCT/US1998/004080 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same WO1998039464A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98907702A EP1007715A2 (en) 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU63450/98A AU744725B2 (en) 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
JP53867498A JP2002514074A (en) 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcriptional regulatory elements and methods of using the same
CA002283231A CA2283231C (en) 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US3976397P 1997-03-03 1997-03-03
US3976297P 1997-03-03 1997-03-03
US60/039,763 1997-03-03
US60/039,762 1997-03-03
US5452397P 1997-08-04 1997-08-04
US60/054,523 1997-08-04
US09/033,556 US6432700B1 (en) 1997-03-03 1998-03-02 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US09/033,556 1998-03-02

Publications (4)

Publication Number Publication Date
WO1998039464A2 WO1998039464A2 (en) 1998-09-11
WO1998039464A3 true WO1998039464A3 (en) 1999-01-07
WO1998039464A9 WO1998039464A9 (en) 1999-02-18
WO1998039464A8 WO1998039464A8 (en) 1999-04-01

Family

ID=27488125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004080 WO1998039464A2 (en) 1997-03-03 1998-03-03 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same

Country Status (5)

Country Link
EP (1) EP1007715A2 (en)
JP (1) JP2002514074A (en)
AU (1) AU744725B2 (en)
CA (1) CA2283231C (en)
WO (1) WO1998039464A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991935B2 (en) 1998-12-30 2006-01-31 Cell Genesys, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US11596660B2 (en) 2017-04-14 2023-03-07 Cg Oncology, Inc. Methods of treating bladder cancer

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968298A2 (en) * 1997-03-03 2000-01-05 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
DE69838584T2 (en) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
CA2342396A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
WO2000022124A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
CN101092636B (en) * 1998-10-15 2012-08-08 坎吉有限公司 Selectively replicating viral vectors, preparation method and application
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
GB9906815D0 (en) * 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
EP1266022B1 (en) * 2000-03-24 2008-10-22 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP1318839A2 (en) * 2000-03-24 2003-06-18 Cell Genesys, Inc. Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
US6673614B2 (en) 2000-06-27 2004-01-06 Cell Genesys, Inc. Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody
CA2424178A1 (en) * 2000-09-30 2002-04-11 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
WO2002068627A2 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constucts
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
WO2004042025A2 (en) 2002-11-01 2004-05-21 Cell Genesys, Inc. Cell-specific adenovirus vector comprising ebv-specific promoter
EP1597354A4 (en) * 2003-02-24 2008-07-02 Cell Genesys Inc System for external control of oncolytic virus replication
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP2486137B1 (en) * 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003594A1 (en) * 1992-08-07 1994-02-17 University Of Manitoba Androgen regulation with dna sequences of rat probasin gene
WO1995014100A2 (en) * 1993-11-19 1995-05-26 The Wellcome Foundation Limited Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting
WO1996017053A1 (en) * 1994-11-28 1996-06-06 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors
WO1997001358A1 (en) * 1995-06-27 1997-01-16 Calydon Tissue specific viral vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) * 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003594A1 (en) * 1992-08-07 1994-02-17 University Of Manitoba Androgen regulation with dna sequences of rat probasin gene
WO1995014100A2 (en) * 1993-11-19 1995-05-26 The Wellcome Foundation Limited Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting
WO1996017053A1 (en) * 1994-11-28 1996-06-06 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors
WO1997001358A1 (en) * 1995-06-27 1997-01-16 Calydon Tissue specific viral vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARBUTHNOT P. B. ET AL.: "In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector.", HUMAN GENE THERAPY, vol. 7, no. 13, August 1996 (1996-08-01), pages 1503 - 1514, XP002071007 *
CHEN L. ET AL.: "Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/ MUC1 promoter.", JOURNAL OF CLINICAL INVESTIGATION, vol. 96, no. 6, December 1995 (1995-12-01), pages 2775 - 2782, XP002071017 *
MANOME Y. ET AL.: "Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir.", CANCER RESEARCH, vol. 54, 1994, pages 5408 - 5413, XP002071008 *
MURTHA P. ET AL.: "Androgen induction of a human prostate-specific kallikkrein, hKLK2: Characterization of an androgen response element in the 5' promoter region of the gene.", BIOCHEMISTRY, vol. 32, 1993, pages 6459 - 6464, XP002071006 *
TOLLEFSON A. E. ET AL.: "The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells.", JOURNAL OF VIROLOGY, vol. 70, no. 4, April 1996 (1996-04-01), pages 2296 - 2306, XP002071004 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991935B2 (en) 1998-12-30 2006-01-31 Cell Genesys, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US12090183B2 (en) 2016-03-10 2024-09-17 Cg Oncology, Inc. Methods of treating solid or lymphatic tumors by combination therapy
US11596660B2 (en) 2017-04-14 2023-03-07 Cg Oncology, Inc. Methods of treating bladder cancer
US12370229B2 (en) 2017-04-14 2025-07-29 Cg Oncology, Inc. Methods of treating bladder cancer

Also Published As

Publication number Publication date
WO1998039464A8 (en) 1999-04-01
AU744725B2 (en) 2002-02-28
CA2283231A1 (en) 1998-09-11
JP2002514074A (en) 2002-05-14
CA2283231C (en) 2008-05-20
EP1007715A2 (en) 2000-06-14
AU6345098A (en) 1998-09-22
WO1998039464A2 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
WO1998039464A8 (en) Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO2001023597A3 (en) Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
WO2000034496A3 (en) Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene
DE69634752D1 (en) ADENOVIRAL VECTORS CONTAINING A PROSTATE SPECIFIC ANTIGEN (PSA) "RESPONSE ELEMENT"
WO2000039319A3 (en) Target cell-specific adenoviral vectors containing e3 and methods of use thereof
ES2151310T3 (en) NEW CELLULAR COMPLEMENTATION LINES FOR DEFECTIVE ADENOVIRAL VECTORS.
FR2704234B1 (en) RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
CA2311643A1 (en) Compositions and methods for inducing gene expression
AU2001294624A1 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
AU3625997A (en) Chimeric gene containing several herbicide tolerance genes, plant cell and plant which are tolerant to several herbicides
WO1998039467A3 (en) Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
DK136184A (en) PROCEDURE FOR EXPRESSING A GENE CODING PROCHYMOSIN, IN E.COLI HOST CELLS AND EXPRESSION PLASMID USED BY THE PROCEDURE
WO2001036650A3 (en) An oncolytic adenovirus
AU5588298A (en) Adeno-associated viral vector-mediated delivery of dna to cells of the liver
NZ508399A (en) Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
WO2006065827A3 (en) Cell lines for production of replication-defective adenovirus
WO2005052143A3 (en) Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
AU5551996A (en) An adenovirus helper-virus system
WO2003099859A3 (en) Novel use of adenoviruses and nucleic acids coding therefor
WO2000040741A3 (en) Lentivirus vector system
WO2004015086A3 (en) Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
WO2000012741A3 (en) Inducible expression system
DK0880594T3 (en) Retroviral vector and its use in gene therapy
AU2890495A (en) Nucleic acid fragments and corresponding peptide fragments from the caprine arthritis-encephalitis virus (caev) genome, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/18-18/18, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 36/98 UNDER (30) REPLACE "NOT FURNISHED" BY "09/033556"

ENP Entry into the national phase

Ref document number: 2283231

Country of ref document: CA

Ref country code: CA

Ref document number: 2283231

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998907702

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 63450/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998907702

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 63450/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1998907702

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998907702

Country of ref document: EP